Organon: A Look Beyond The Dividend Cut

Organon & Co. (OGN) has experienced a significant stock decline since its spin-off from Merck, exacerbated by a recent dividend cut to prioritize debt repayment following the Dermavant acquisition, leading to a shareholder lawsuit. While the established brands segment faces headwinds from loss of exclusivity, growth in biosimilars and women's health, particularly Nexplanon, is offsetting some declines; analysts project flat topline growth but higher bottom-line growth due to cost-saving initiatives. Despite these challenges and high leverage, OGN's valuation, currently trading at a low 2.6x non-GAAP forward PE ratio, is considered attractive, potentially offering a buying opportunity amid market negativity.

Analysis

Organon & Co. (OGN), since its June 2021 spin-off from Merck & Co., has experienced a substantial stock price decline of approximately 70%, recently exacerbated by a 27% single-day drop following a dividend cut aimed at prioritizing debt repayment. This strategic shift was influenced by the acquisition of Dermavant, which increased net leverage from 4.0x to approximately 4.2x, with potential to reach 4.7x considering remaining milestone payments. The company operates through three segments: 'Established Brands', which faces continued headwinds from loss of exclusivity (LOE) – notably, the LOE for Atozet in Europe and Japan is expected to create a ~$200 million topline headwind in 2025; 'Biosimilars', which is a key growth engine with market growth projected at 17-18% CAGR; and 'Women’s Health', where Nexplanon is a standout performer, generating $963 million in 2024 revenue (a ~17% increase) and projected to exceed $1 billion in 2025, with IP protection until 2030. While analysts project flat topline growth for several years, bottom-line growth is anticipated due to cost-saving initiatives and debt reduction. Despite these challenges, including a class action lawsuit concerning misleading statements about capital allocation, OGN trades at a significantly low 2.6x non-GAAP forward P/E ratio, well below its sector median of ~17.7x and its own 5-year average of 4.8x, leading to a Seeking Alpha Quant A+ valuation grade, suggesting a potentially undervalued stock amidst market pessimism.

Key Decisions for Investors

• Investors should consider the deeply discounted valuation, evidenced by a 2.6x forward P/E, as a potential entry point, while carefully weighing the risks associated with high leverage, ongoing loss of exclusivity in the established brands segment, and the pending class action lawsuit.
• Monitor OGN's progress on deleveraging, the growth trajectory and market penetration of its Biosimilars and Women's Health segments, particularly Nexplanon's performance, and any significant developments related to the shareholder litigation.
• Acknowledge that the recent dividend cut from $0.28 to $0.02 per quarter reflects a strategic pivot towards strengthening the balance sheet, making the stock less attractive for income-focused investors in the near term but potentially beneficial for long-term capital appreciation if turnaround efforts succeed.